Results 241 to 250 of about 2,529,164 (287)
Some of the next articles are maybe not open access.
Sleep
Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those ...
Richard Bogan +5 more
semanticscholar +1 more source
Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those ...
Richard Bogan +5 more
semanticscholar +1 more source
Sleep
In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
B. Corser +8 more
semanticscholar +1 more source
In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
B. Corser +8 more
semanticscholar +1 more source
Sleep
Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs).
Adrian Santamaria +7 more
semanticscholar +1 more source
Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs).
Adrian Santamaria +7 more
semanticscholar +1 more source
Sleep
Narcolepsy is a chronic neurological condition associated with excessive daytime sleepiness (EDS), sleep fragmentation, and features of rapid eye movement (REM) dissociation.
Pratik Pohuja +4 more
semanticscholar +1 more source
Narcolepsy is a chronic neurological condition associated with excessive daytime sleepiness (EDS), sleep fragmentation, and features of rapid eye movement (REM) dissociation.
Pratik Pohuja +4 more
semanticscholar +1 more source
The American journal of cardiology, 1998
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, was used alone or in combination with a statin (inhibitor of hydroxymethylglutaryl coenzyme A reductase),
J R, Guyton +5 more
openaire +1 more source
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, was used alone or in combination with a statin (inhibitor of hydroxymethylglutaryl coenzyme A reductase),
J R, Guyton +5 more
openaire +1 more source
Endocrine Practice, 2012
To observe the effect of the dawn phenomenon on basal glucose and postbreakfast hyperglycemia in patients with type 1 diabetes treated with once-nightly insulin glargine and premeal insulin lispro.In 49 study subjects consuming a fixed isocaloric (50% carbohydrate) diet of usual food, the insulin glargine dose was titrated from daily continuous glucose
Allen B, King +2 more
openaire +2 more sources
To observe the effect of the dawn phenomenon on basal glucose and postbreakfast hyperglycemia in patients with type 1 diabetes treated with once-nightly insulin glargine and premeal insulin lispro.In 49 study subjects consuming a fixed isocaloric (50% carbohydrate) diet of usual food, the insulin glargine dose was titrated from daily continuous glucose
Allen B, King +2 more
openaire +2 more sources
Sleep
Narcolepsy is a chronic neurologic condition of excessive daytime sleepiness (EDS), disturbed nocturnal sleep, and REM dissociation. In 2002, Xyrem (sodium oxybate) was approved by the U.S Food and Drug Administration (FDA) for treatment of EDS and
Gerard J. Meskill +3 more
semanticscholar +1 more source
Narcolepsy is a chronic neurologic condition of excessive daytime sleepiness (EDS), disturbed nocturnal sleep, and REM dissociation. In 2002, Xyrem (sodium oxybate) was approved by the U.S Food and Drug Administration (FDA) for treatment of EDS and
Gerard J. Meskill +3 more
semanticscholar +1 more source
Pneumologie (Stuttgart, Germany), 1992
Many patients with asthma often experience a deterioration of symptoms at night and in the early morning resulting in sleep disruption and possibly impaired daily performance. A bronchodilator agent which exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the ...
V W, Steinijans +4 more
openaire +1 more source
Many patients with asthma often experience a deterioration of symptoms at night and in the early morning resulting in sleep disruption and possibly impaired daily performance. A bronchodilator agent which exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the ...
V W, Steinijans +4 more
openaire +1 more source
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Data From RESTORE
Sleep Medicine, 2022T. Stern +8 more
openaire +1 more source